1. DURABILITY OF COMPLETE RESPONSE AFTER BLINATUMOMAB THERAPY FOR REFRACTORY/RELAPSED AGGRESSIVE B‐CELL NON‐HODGKIN LYMPHOMA. (12th June 2019) Authors: Viardot, A.; Hess, G.; Bargou, R.; Morley, N.J.; Gritti, G.; Iskander, K.; Cohan, D.; Zhang, A.; Franklin, J.; Coyle, L. Journal: Hematological oncology Issue: Volume 37(2019)Supplement 2 Page Start: 429 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Modern multiple myeloma therapy: deep, sustained treatment response and good clinical outcomes. (16th February 2017) Authors: Landgren, O.; Iskander, K. Journal: Journal of internal medicine Issue: Volume 281:Number 4(2017) Page Start: 365 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗